Literature DB >> 33816158

Magnetic resonance quantitative susceptibility mapping in the evaluation of hepatic fibrosis in chronic liver disease: a feasibility study.

Zheng Qu1, Shuohui Yang2, Feng Xing3, Rui Tong1, Chenyao Yang2, Rongfang Guo2, Jiling Huang2, Fang Lu2, Caixia Fu4, Xu Yan4, Stefanie Hectors5, Kelly Gillen5, Yi Wang5,6, Chenghai Liu3,7, Songhua Zhan2, Jianqi Li1.   

Abstract

BACKGROUND: Noninvasive methods for the early diagnosis and staging of hepatic fibrosis are needed. The present study aimed to investigate the alteration of magnetic susceptibility in the liver of patients with various fibrosis stages and to evaluate the feasibility of using susceptibility to stage hepatic fibrosis.
METHODS: A total of 30 consecutive patients with chronic liver diseases (CLDs) underwent magnetic resonance imaging (MRI) and liver biopsy evaluation of hepatic fibrosis, necroinflammatory activity, iron load, and steatosis. Quantitative susceptibility mapping (QSM), R2* and proton density fat fraction (PDFF) images were postprocessed from the same gradient-echo data for quantitative tissue characterization using region of interest (ROI) analysis. The differences for MRI measurements between cohorts of non-significant (Ishak-F <3) and significant fibrosis (Ishak-F ≥3) and the correlation of MRI measurements with fibrosis stages and necroinflammatory activity grades were tested. Receiver operating characteristic (ROC) analysis was also performed.
RESULTS: There was a significant difference in liver susceptibility between the cohorts of significant and non-significant fibrosis (Z=-2.880, P=0.004). A moderate negative correlation between the stages of liver fibrosis and liver susceptibility was observed (r=-0.471, P=0.015). Liver magnetic susceptibility differentiated non-significant from significant hepatic fibrosis with an area under the receiver operating curve (AUC) of 0.836 (P=0.004). A highly sensitive diagnostic performance with an AUC of 0.933 was obtained using magnetic susceptibility and PDFF together (P<0.001).
CONCLUSIONS: A noninvasive liver QSM-based evaluation promises an accurate assessment of significant fibrosis in patients with CLDs. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Chronic liver disease (CLD); fibrosis; liver; quantitative susceptibility mapping (QSM)

Year:  2021        PMID: 33816158      PMCID: PMC7930689          DOI: 10.21037/qims-20-720

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  53 in total

1.  An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

Authors:  P Bedossa; T Poynard
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

2.  Susceptibility underestimation in a high-susceptibility phantom: Dependence on imaging resolution, magnitude contrast, and other parameters.

Authors:  Dong Zhou; Junghun Cho; Jingwei Zhang; Pascal Spincemaille; Yi Wang
Journal:  Magn Reson Med       Date:  2016-10-03       Impact factor: 4.668

3.  Imaging diamagnetic susceptibility of collagen in hepatic fibrosis using susceptibility tensor imaging.

Authors:  Hongjiang Wei; Kyle Decker; Hien Nguyen; Steven Cao; Tsung-Yuan Tsai; Cynthia Dianne Guy; Mustafa Bashir; Chunlei Liu
Journal:  Magn Reson Med       Date:  2019-10-21       Impact factor: 4.668

4.  A novel background field removal method for MRI using projection onto dipole fields (PDF).

Authors:  Tian Liu; Ildar Khalidov; Ludovic de Rochefort; Pascal Spincemaille; Jing Liu; A John Tsiouris; Yi Wang
Journal:  NMR Biomed       Date:  2011-03-08       Impact factor: 4.044

5.  Evolution of hepatic fibrosis research.

Authors:  Norifumi Kawada
Journal:  Hepatol Res       Date:  2011-03       Impact factor: 4.288

6.  Clinical Integration of Automated Processing for Brain Quantitative Susceptibility Mapping: Multi-Site Reproducibility and Single-Site Robustness.

Authors:  Pascal Spincemaille; Zhe Liu; Shun Zhang; Ilhami Kovanlikaya; Matteo Ippoliti; Marcus Makowski; Richard Watts; Ludovic de Rochefort; Vijay Venkatraman; Patricia Desmond; Mathieu D Santin; Stéphane Lehéricy; Brian H Kopell; Patrice Péran; Yi Wang
Journal:  J Neuroimaging       Date:  2019-08-04       Impact factor: 2.486

7.  Evaluation of fibrotic liver disease with whole-liver T1ρ MR imaging: a feasibility study at 1.5 T.

Authors:  Thomas Allkemper; Florian Sagmeister; Vito Cicinnati; Susanne Beckebaum; Hendrik Kooijman; Christian Kanthak; Christoph Stehling; Walter Heindel
Journal:  Radiology       Date:  2013-12-13       Impact factor: 11.105

8.  Joint estimation of chemical shift and quantitative susceptibility mapping (chemical QSM).

Authors:  Alexey V Dimov; Tian Liu; Pascal Spincemaille; Jacob S Ecanow; Huan Tan; Robert R Edelman; Yi Wang
Journal:  Magn Reson Med       Date:  2014-06-19       Impact factor: 4.668

9.  Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.

Authors:  Wai-Kay Seto; Rex W H Hui; Lung-Yi Mak; James Fung; Ka-Shing Cheung; Kevin S H Liu; Danny Ka-Ho Wong; Ching-Lung Lai; Man-Fung Yuen
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-29       Impact factor: 11.382

10.  The effect of low resolution and coverage on the accuracy of susceptibility mapping.

Authors:  Anita Karsa; Shonit Punwani; Karin Shmueli
Journal:  Magn Reson Med       Date:  2018-10-19       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.